

27 March 2018 | CannPal Animal Therapeutics Limited ACN: 612 791 518 | ASX:CP1

CannPal Successfully Imports Cannabis Oils for Clinical Trial of Lead Drug Candidate

Key Highlights

- CannPal has been granted export permits by Health Canada for its medical cannabis oil formulations
- Oils have now arrived in Sydney, Australia and are in transit to a purpose-built research facility for the clinical phase of the Company's research
- cGMP accredited licensed producer Aphria Inc (TSE:APH), has provided the clinical trial material for the studies
- CannPal has completed the dog selection process and is in the last stage of preparation for the live phase of its research
- CannPal is assessing the pharmacokinetic and safety profile of its proprietary cannabinoid formulations
- The live phase of the research is set to commence on the week starting April 2nd

27th March 2018: Animal health company **CannPal Animal Therapeutics Limited (ASX:CP1)** ("CannPal" or "the Company") is pleased to announce that it has imported its first medical cannabis oil formulations, having recently received export permits from Health Canada. The oils will be used in the clinical phase of research for the Company's lead drug candidate, CPAT-01.

Aphria Inc. (TSE:APH) ("Aphria") is providing the clinical trial material for the Company's studies. Aphria recently became the first Canadian licensed producer to receive current Good Manufacturing Practice (cGMP) accreditation from internationally renowned firm SGS. The certification is to United States Food and Drug Administration (USFDA) cGMP standards, which are internationally-recognised for the safe and consistent production of pharmaceutical grade medicines.

CannPal has completed the dog selection process for the live phase of the research and is in the last stage of preparation for the study, which is being carried out in a purpose-built research facility in NSW. CannPal has entered into service agreements with a number of specialised pharmaceutical analytical companies to complete various bioanalytical services for the study.

The study will be carried out in 2 phases, with 11 dogs enrolled for phase 1 and 48 dogs enrolled for phase 2. Researchers will be assessing the pharmacokinetic and safety profiles for the Company's proprietary cannabinoid formulations, with blood sample analysis expected to be completed by May 2018.

Dosing of the dogs is expected to commence on the week starting April 2nd.



CPAT-01 is a cannabis-derived medicine being developed as a treatment for pain in companion animals. Currently, Non-Steroidal Anti-Inflammatories (NSAID's) are the most commonly used treatments for pain management in dogs and cats, but these come with a long list of side effects. The global market for pain treatment in companion animals was recently estimated to be worth over US\$1.4 billion.

CannPal's Founder and Managing Director Layton Mills: "CannPal is delighted to have successfully imported the oils for our first clinical trial for CPAT-01. With the oils now in Australia and the dog selection complete we are all set to commence the live phase of our clinical research. Our study is the first of its kind in Australia and is one that we hope will result in the creation of a safe, efficacious pain treatment for companion animals that will meet full regulatory approval. We look forward to updating the market on the study's progress."

About CannPal Animal Therapeutics

CannPal Animal Therapeutics Limited (ASX: CP1) is a pharmaceutical-focused animal health Company researching the benefits of medical cannabis for companion animals.

CannPal is researching and developing medicines derived from cannabinoids to provide veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.

CannPal has identified a significant opportunity to benefit from the rapidly growing medical cannabis and health markets by developing innovative therapeutics derived from the cannabis plant. The Company is working closely with regulatory authorities and veterinary research organisations conducting clinical trials to commercialise therapeutic products that will meet regulatory approval and support the health and well-being of companion animals.

To learn more please visit: www.cannpal.com

END

For further information, please contact:

CannPal

Layton Mills
Founder and Managing Director
M: +61 431 302 667
E: layton@cannpal.com

Media enquiries

Julia Maguire
The Capital Network
M: +61 419 815 386
E: julia@thecapitalnetwork.com.au



@CannPalAT



facebook.com/CannPal

